Daily Stock Analysis, GERN, Geron Corp, priceseries

Geron Corp. Daily Stock Analysis
Stock Information
Open
1.74
Close
1.77
High
1.80
Low
1.71
Previous Close
1.74
Daily Price Gain
0.03
YTD High
2.14
YTD High Date
Apr 11, 2019
YTD Low
0.98
YTD Low Date
Jan 2, 2019
YTD Price Change
0.73
YTD Gain
70.19%
52 Week High
6.99
52 Week High Date
Sep 13, 2018
52 Week Low
0.95
52 Week Low Date
Dec 21, 2018
52 Week Price Change
-2.02
52 Week Gain
-53.30%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 11. 2017
2.68
May 26. 2017
2.93
11 Trading Days
9.40%
Link
LONG
Jan 22. 2018
1.97
Feb 8. 2018
2.42
13 Trading Days
23.09%
Link
LONG
Feb 28. 2018
2.31
Mar 28. 2018
4.53
20 Trading Days
96.17%
Link
LONG
Apr 12. 2018
3.99
Apr 13. 2018
4.30
1 Trading Days
7.89%
Link
LONG
May 21. 2018
3.63
May 31. 2018
4.10
7 Trading Days
12.85%
Link
LONG
Jan 31. 2019
1.15
Feb 28. 2019
1.48
19 Trading Days
28.94%
Link
LONG
Mar 11. 2019
1.49
Mar 25. 2019
1.62
10 Trading Days
8.91%
Link
LONG
Apr 2. 2019
1.74
Apr 15. 2019
1.86
9 Trading Days
6.93%
Link
Company Information
Stock Symbol
GERN
Exchange
NasdaqGS
Company URL
http://www.geron.com
Company Phone
6504737700
CEO
John A. Scarlett
Headquarters
California
Business Address
149 COMMONWEALTH DRIVE, SUITE 2070, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000886744
About

Geron Corp. discovers and develops therapeutic products for cancer. It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Description

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.